Roche Reveals Development Strategies In China
This article was originally published in PharmAsia News
Shanghai Roche Pharmaceuticals CEO Zhou Ping-Shan has revealed the company's development plans in China in a recent interview. First is focus: Roche enjoys a leading position in such key therapeutic areas as oncology, virology and transplant by relying on its strong R&D and innovative capability. It is committed to promoting local pharmaceutical industry innovation and has set up an R&D center as well as a pharmaceutical development center. Second is the company's emphasis on collaboration with the Chinese biopharmaceutical industry. Roche has built up close partnerships with local universities, academic institutions and biopharmaceutical enterprises. Zhou notes that pharmaceutical enterprises must adapt rapidly to China's policy and reform as the nation's health care is in a revolutionary stage. (Click here for more - Chinese Language)
You may also be interested in...
Given its ever-growing role as a critical component of the global biopharma industry, you can’t afford not to be up to speed on Asia. This biweekly selection of insights from our experienced on-the-ground team will help.
Becton Dickinson will spend $1.2bn over the next four years to improve its drug-delivery device manufacturing capabilities. See what Eric Borin, president of BD, said about it here.
Pfizer is producing vaccine doses at scale now that it has buttoned down the manufacturing process.